MARKSANS Marksans Pharma Q1 FY27 results (Apr–Jun 2026) and concall
Marksans Pharma Limited delivered a very strong Q1 FY27, with significant year-on-year growth across revenue, EBITDA, and PAT, primarily driven by exceptional performance in the UK and Europe. The company's cash balance surpassed ₹1,000 crores for the first time, reflecting improved profitability and cash generation. Strategic investments and recent acquisitions in Europe are yielding positive results, though geopolitical factors pose some margin and market challenges.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 0.3%, net profit up 43.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 309 | 312 | 299 | 320 | 320 +4% | 340 +9% | 362 +21% | 321 +0% |
| EBITDA | 63 | 60 | 52 | 70 | 72 +14% | 75 +25% | 106 +104% | 82 +17% |
| Net profit | 63 | 55 | 38 | 48 | 100 +59% | 61 +11% | 92 +142% | 69 +44% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
